Drugs Made in America Acquisition Corp. II (Ticker: DMIIU US) is a Cayman Islands–incorporated special purpose acquisition company (SPAC) formed to target acquisitions in the pharmaceutical sector. The company is set to list on NASDAQ on September 25, 2025, offering 50.0 million units at $10.00 each to raise $500 million. Each unit includes one ordinary share and one right to receive one-tenth of an ordinary share upon completion of a business combination. Drugs Made in America Acquisition Corp. II does not have operating revenues, as it is a blank check company established in 2024. The offering is led by Cantor, and the proceeds will be used to fund the company’s search for and merger with a pharmaceutical business target.